Related Experiment Videos
Reversibility of left ventricular hypertrophy
1Royal Brompton and National Heart-Chest Hospital, London, UK.
Blood Pressure. Supplement
|January 1, 1992
Summary
Antihypertensive therapies can reverse left ventricular hypertrophy (LVH), a risk factor for heart disease. Combination therapy, ACE inhibitors, and methyldopa were most effective, while vasodilators showed no effect on LVH.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Left ventricular hypertrophy (LVH) is a significant independent risk factor for coronary artery disease.
- Effective antihypertensive strategies are crucial for mitigating cardiovascular complications associated with LVH.
Purpose of the Study:
- To evaluate the efficacy of different antihypertensive therapies in reversing left ventricular hypertrophy (LVH).
- To compare the effects of various drug classes on LVH regression using echocardiographic assessments.
Main Methods:
- Systematic review and meta-analysis of 104 studies.
- Echocardiography used to assess left ventricular mass and wall thickness.
- Comparison of antihypertensive drug classes including ACE inhibitors, vasodilators, beta-blockers, and combination therapies.
Main Results:
- Combination therapy, angiotensin-converting enzyme (ACE) inhibitors, and methyldopa demonstrated the most significant LVH reversal.
- Vasodilators (minoxidil, hydralazine) showed no effect on LVH.
- Beta-blockers were comparable to ACE inhibitors in reducing LV wall thickness, independent of blood pressure reduction or therapy duration.
Conclusions:
- Specific antihypertensive drug classes exhibit differential effects on LVH regression.
- Reversal of LVH through antihypertensive therapy may be linked to reduced cardiovascular events.
- Further research into the mechanisms underlying these drug-specific effects is warranted.